home / stock / lly / lly articles

LLY Articles, Eli Lilly and Company - From 06/06/24

Stock Information
Company Name: Eli Lilly and Company
Stock Symbol: LLY
Market: NYSE
Website: lilly.com
Menu
LLY LLY Quote LLY Short LLY News LLY Articles LLY Message Board
Get LLY Alerts

News, Short Squeeze, Breakout and More Instantly...
Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile | Benzinga

On Monday, June 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the dat...
Chinese Generic Ozempic, Wegovy Versions Could Put Novo Nordisk At The Risk Of Stiff Competition In Key Market | Benzinga

Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its...

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? | Benzinga

On Wednesday, the stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) and Sagimet Biosciences Inc (NASDAQ:SGMT) are trading lower. At the EASL Int...

British Agency Supports Eli Lilly's Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk's Wegovy | Benzinga

Britain’s medical costs regulator, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly And Co’s (NY...
Google Parent Alphabet Appoints Eli Lilly's Finance Chief Ashkenazi As CFO | Benzinga

On Wednesday, Eli Lilly And Co (NYSE:LLY) announced that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity...

If You Invested $100 In This Stock 5 Years Ago, You Would Have $700 Today | Benzinga

Eli Lilly and Co (NYSE:LLY) has outperformed the market over the past 5 years by 35.98% on an annualized basis producing an average annual return o...

Structure Therapeutics' Obesity Candidate Is ' Very Competitive' To Eli Lilly's Orforglipron, Analyst Says | Benzinga

On Monday, Structure Therapeutics Inc. (NASDAQ:GPCR) revealed 12-week topline obesity data from its Phase 2a study of GSBR-1290. In the Phase ...
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect | Benzinga

On Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli Lilly and Co. (NYSE:LLY). QurAlis has grant...

Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes | Benzinga

Novo Nordisk A/S (NYSE:NVO) has reportedly filed lawsuits against nine additional U.S. medical spas, wellness clinics, and pharmacies for selling p...

Performance Comparison: Eli Lilly and Co And Competitors In Pharmaceuticals Industry | Benzinga

In the ever-evolving and intensely competitive business landscape, conducting a thorough company analysis is of utmost importance for investors and...
Previous 10 Next 10